Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach

References

• Miller DT, Freedenberg D, Schorry E, et al. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019;143(5):e20190660. doi:10.1542/peds.2019-0660
   PubMed Web of Science ®Google Scholar
• Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834–843. PMID: 25030515. doi:10.1016/S1474-4422(14)70063-8
   PubMed Web of Science ®Google Scholar
• Wang W, Wei C-J, Cui X-W, et al. Impacts of NF1 gene mutations and genetic modifiers in neurofibromatosis type 1. Front Neurol. 2021:12. doi:10.3389/fneur.2021.704639
   Web of Science ®Google Scholar
• Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506–1513. doi:10.1038/s41436-021-01170-5
   PubMed Web of Science ®Google Scholar
• House RJ, Tovar EA, Essenburg CJ, et al. NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. bioRxiv. 2023;2023:1. doi:10.1101/2023.11.24.568339
   Google Scholar
• Poplausky D, Young JN, Tai H, Rivera-Oyola R, Gulati N, Brown RM. Dermatologic manifestations of neurofibromatosis type 1 and emerging treatments. Cancers. 2023;15(10):2770. doi:10.3390/cancers15102770
   PubMed Web of Science ®Google Scholar
• Chelleri C, Scala M, De Marco P, et al. Somatic double inactivation of NF1 associated with NF1-related pectus excavatum deformity. Hum Mutat. 2023;2023:2023–2030. doi:10.1155/2023/3160653
   Web of Science ®Google Scholar
• Garg S, Green J. Learning Disabilities and Behaviour in Neurofibromatosis Type 1 Patients. In: Tadini G, Legius E, Brems H editors. Multidisciplinary Approach to Neurofibromatosis Type 1. Springer; 2020. doi:10.1007/978-3-319-92450-2_14
   Google Scholar
• Scala M, Schiavetti I, Madia F, et al. Genotype-phenotype correlations in neurofibromatosis type 1: a single-center cohort study. Cancers. 2021;13(8):1879. doi:10.3390/cancers13081879
   PubMed Web of Science ®Google Scholar
• Yoo HK, Porteous A, Ng A, et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurol. 2023;23:419. doi:10.1186/s12883-023-03429-7
   PubMed Web of Science ®Google Scholar
• Pasmant E, Vidaud M, Vidaud D, et al. Neurofibromatosis type 1: from genotype to phenotype. J Med Genet. 2012;49:483–489. doi:10.1136/jmedgenet-2012-100978
   PubMed Web of Science ®Google Scholar
• Anastasaki C, Orozco P, Gutmann DH. RAS and beyond: the many faces of the neurofibromatosis type 1 protein. Dis Model Mech. 2022;15(2):dmm049362. doi:10.1242/dmm.049362
   PubMed Web of Science ®Google Scholar
• Ejerskov C, Raundahl M, Gregersen PA, et al. Clinical features and disease severity in patients with mosaic neurofibromatosis type 1: a single-center study and literature review. Orphanet J Rare Dis. 2021;16:180. doi:10.1186/s13023-021-01796-3
   PubMed Web of Science ®Google Scholar
• Tamura R. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int J Mol Sci. 2021;22(11):5850. doi:10.3390/ijms22115850
   PubMed Web of Science ®Google Scholar
• Ejerskov C, Krogh K, Ostergaard JR, Joensson I, Haagerup A. Gastrointestinal Symptoms in Children and Adolescents With Neurofibromatosis Type 1. J Pediatr Gastroenterol Nutr. 2018;66(6):872–875. doi:10.1097/MPG.0000000000001860
   PubMed Web of Science ®Google Scholar
• Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro-Oncology. 24(11):1827–44. 10.1093/neuonc/noac146.
   PubMed Web of Science ®Google Scholar
• Brown R. Management of central and peripheral nervous system tumors in patients with neurofibromatosis. Curr Oncol Rep. 2023;2023:1.
   Google Scholar
• Szymanski JJ, Sundby RT, Jones PA, et al. Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: a cross-sectional study. PLoS Med. 2021;18(8):e1003734. doi:10.1371/journal.pmed.1003734
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. FDA website; 2020. Accessed from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas. Accessed April 09, 2024.
   Google Scholar
• Jackson S, Baker EH, Gross AM, et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neuro-Oncol Adv. 2020;2(1):vdaa095. doi:10.1093/noajnl/vdaa095
   PubMedGoogle Scholar
• Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430–1442. doi:10.1056/NEJMoa1912735
   PubMed Web of Science ®Google Scholar
• Garozzo D, Ali ZS, Zager EL. Management of MPNST in Neurofibromatosis. In: Diagnostic Assessment and Treatment of Peripheral Nerve Tumors. Cham: Springer; 2021:361–370. doi:10.1007/978-3-030-77633-6_29
   Google Scholar
• Knight SWE, Knight TE, Santiago T, et al. Malignant Peripheral Nerve Sheath Tumors-A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management. Children. 2022;9:1.
   Google Scholar
• Cannon A, Chen MJ, Li P, et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis. 2018;13:31. doi:10.1186/s13023-018-0772-z
   PubMed Web of Science ®Google Scholar
• Chaudhary M, Dixit Chaudhary S, Choudhary A, et al. Discrete subcutaneous neurofibroma of skin associated with neurofibromatosis 1, along with solitary neurofibroma involving the tongue —an unusual case report. IOSR J Dent Med Sci. 2016;15:88–91. doi:10.9790/0853-1506068891
   Google Scholar
• Chamseddin BH, Le LQ. Management of cutaneous neurofibroma: current therapy and future directions. Neurooncol Adv. 2020;2(Supplement_1):i107–i116. doi:10.1093/noajnl/vdz034
   PubMedGoogle Scholar
• Shofty B, Ben Sira L, Constantini S. Neurofibromatosis 1–associated optic pathway gliomas. Childs Nerv Syst. 2020;36(10):2351–2361. doi:10.1007/s00381-020-04697-1
   PubMed Web of Science ®Google Scholar
• De Andrade Costa A, Gutmann DH. Brain tumors in neurofibromatosis type 1. Neurooncol Adv. 2020;2(Supplement_1):i85–i97. doi:10.1093/noajnl/vdz040
   Google Scholar
• Thomas S, Bikeyeva V, Abdullah A, et al. Systematic review of pediatric brain tumors in neurofibromatosis type 1: status of gene therapy. Cureus. 2022;14(8):e27963. doi:10.7759/cureus.27963
   PubMed Web of Science ®Google Scholar
• Samples DC, Mulcahy Levy JM, Hankinson TC. Neurosurgery for optic pathway glioma: optimizing multidisciplinary management. Frontiers in Surgery. 2022;9. doi:10.3389/fsurg.2022.884250
   Web of Science ®Google Scholar
• Sellmer L, Farschtschi S, Marangoni M, et al. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet J Rare Dis. 2018;13:62. doi:10.1186/s13023-018-0811-9
   PubMed Web of Science ®Google Scholar
• Momen AI, Muir RT, Barnett C, Sundaram ANE. Homonymous retinal ganglion cell layer atrophy with asymptomatic optic tract glioma in neurofibromatosis type I. Front Neurol. 2020;11:11. doi:10.3389/fneur.2020.00256
   PubMed Web of Science ®Google Scholar
• Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747–754. doi:10.3171/jns.1997.86.5.0747
   PubMed Web of Science ®Google Scholar
• Bayat M, Bayat A. Neurological manifestations of neurofibromatosis: a review. Neurol Sci. 2020;41:2685–2690. doi:10.1007/s10072-020-04400-x
   PubMed Web of Science ®Google Scholar
• Belsky J, Graham R, Leonard J, et al. Mek-inhibitor monotherapy to treat concurrent optic glioma and metastatic neuroblastoma in a patient with neurofibromatosis type 1 (NF1). Neuro-Oncology. 2018;20(suppl_2):i111. doi:10.1093/neuonc/noy059.374
   Google Scholar
• Kaul A, Toonen JA, Cimino PJ, Gianino SM, Gutmann DH. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro-Oncology. 2015;17(6):843–853. doi:10.1093/neuonc/nou329
   PubMed Web of Science ®Google Scholar
• Maani N, Westergard S, Yang J, et al. NF1 patients receiving breast cancer screening: insights from the Ontario high risk breast screening program. Cancers. 2019;11(5):707. doi:10.3390/cancers11050707
   PubMed Web of Science ®Google Scholar
• Suarez-Kelly LP, Yu L, Kline D, et al. Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. Hered Cancer Clin Pract. 2019;17:12. doi:10.1186/s13053-019-0110-z
   PubMed Web of Science ®Google Scholar
• Chen Y, Porembka JH, Hwang H, Hayes JC. Neurofibroma in the breast: diagnosis and management considerations. J Breas Imaging. 2021;3(3):363–368. doi:10.1093/jbi/wbab008
   PubMedGoogle Scholar
• Pearson A, Proszek P, Pascual J, et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin Cancer Res. 2020;26(3):608–622. doi:10.1158/1078-0432.CCR-18-4044
   PubMed Web of Science ®Google Scholar
• Poredska K, Kunovsky L, Prochazka V, et al. Triple malignancy (NET, GIST and pheochromocytoma) as a first manifestation of neurofibromatosis type-1 in an adult patient. Diagn Pathol. 2019;14:77. doi:10.1186/s13000-019-0848-7
   PubMed Web of Science ®Google Scholar
• Pan D, Liang P, Xiao H. Neurofibromatosis type 1 associated with pheochromocytoma and gastrointestinal stromal tumors: a case report and literature review. Oncol Lett. 2016;12:637–643. doi:10.3892/ol.2016.4670
   PubMed Web of Science ®Google Scholar
• Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30(1):90–96. doi:10.1097/01.pas.0000176433.81079.bd
   PubMed Web of Science ®Google Scholar
• Tomatsu M, Isogaki J, Watanabe T, et al. Multiple gastric gastrointestinal stromal tumors in a patient with neurofibromatosis type 1. Case Reports in Surgery. 2016;2016:1515202. doi:10.1155/2016/1515202
   PubMedGoogle Scholar
• Hurley RH, McCormick M, Elhassan M, Nicholson G. Gastrointestinal stromal tumour as a rare association with neurofibromatosis type 1. J Surg Cas Rep. 2018;2018(2):rjy017. doi:10.1093/jscr/rjy017
   PubMedGoogle Scholar
• Huang WK, Wu CE, Wang SY, et al. Systemic therapy for gastrointestinal stromal tumor: current standards and emerging challenges. Curr Treat Options Oncol. 2022;23:1303–1319. doi:10.1007/s11864-022-00996-8
   PubMed Web of Science ®Google Scholar
• Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14:2. doi:10.1186/s13045-020-01026-6
   PubMed Web of Science ®Google Scholar
• Aygun N, Uludag M. Pheochromocytoma and paraganglioma: from epidemiology to clinical findings. Sisli Etfal Hastanesi tip Bulteni. 2020;54(2):159–168. PMID: 32617052; PMCID: PMC7326683. doi:10.14744/semb.2020.18794
   PubMed Web of Science ®Google Scholar
• Zografos GN, Vasiliadis GK, Zagouri F, et al. Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World J Surg Onc. 2010;8(1):14. doi:10.1186/1477-7819-8-14
   PubMedGoogle Scholar
• Costa MHS, Ortiga-Carvalho TM, Violante AD, Vaisman M, Kim YT, Oda H. Pheochromocytomas and paragangliomas: clinical and genetic approaches. Front Endocrinol. 2015;6:6. doi:10.3389/fendo.2015.00126
   PubMed Web of Science ®Google Scholar
• Petr EJ, Else T. Pheochromocytoma and paraganglioma in neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening. Clin Diabetes Endocrinol. 2018;4:15. doi:10.1186/s40842-018-0065-4
   PubMedGoogle Scholar
• Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021;23:1995–2019. doi:10.1007/s12094-021-02622-9
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Pheochromocytoma and Paraganglioma Treatment; 2023. Available from: https://www.cancer.gov/types/pheochromocytoma/patient/pheochromocytoma-treatment-pdq. Accessed April 09, 2024.
   Google Scholar
• Liu Y, Liu L, Zhu F. Therapies targeting the signal pathways of pheochromocytoma and paraganglioma. Onco Targets Ther. 2019;12:7227–7241. doi:10.2147/OTT.S219056
   PubMed Web of Science ®Google Scholar
• Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur J Nucl Med Mol Imaging. 2022;49:1595–1606. doi:10.1007/s00259-021-05632-5
   PubMed Web of Science ®Google Scholar
• Suh YJ, Choe JY, Park HJ. Malignancy in pheochromocytoma or paraganglioma: integrative analysis of 176 Cases in TCGA. Endocr Pathol. 2017;28:159–164. doi:10.1007/s12022-017-9479-2
   PubMed Web of Science ®Google Scholar
• Dayal Y, Tallberg KA, Nunnemacher G, DeLellis RA, Wolfe HJ. Duodenal carcinoids in patients with and without neurofibromatosis. A comparative study. Am J Surg Pathol. 1986;10:348–357. doi:10.1097/00000478-198605000-00007
   PubMed Web of Science ®Google Scholar
• Levy AD, Sobin LH. Gastrointestinal carcinoids: imaging features with clinicopathologic comparison. RadioGraphics. 2007;27(1):237–257. doi:10.1148/rg.271065169
   PubMed Web of Science ®Google Scholar
• Karatzas G, Kouraklis G, Karayiannakis A, Patapis P, Givalos N, Kaperonis E. Ampullary carcinoid and jejunal stromal tumour associated with von Recklinghausen’s disease presenting as gastrointestinal bleeding and jaundice. Europ J Surg Oncol. 2000;26(4):428–429. doi:10.1053/ejso.1999.0911
   PubMedGoogle Scholar
• Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753–766. doi:10.1097/MPA.0b013e3181ebb2a5
   PubMed Web of Science ®Google Scholar
• Relles D, Baek J, Witkiewicz A, et al. Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases. J Gastrointest Surg. 2010;14:1052–1061. doi:10.1007/s11605-009-1123-0
   PubMed Web of Science ®Google Scholar
• Kulke MH. Somatostatin Analogues in Neuroendocrine Tumors. J Natl Compr Cancer Network. 2016;14(3):241–242. doi:10.6004/jnccn.2016.0029
   PubMed Web of Science ®Google Scholar
• Chen C, Dorado Garcia H, Scheer M, Henssen AG. Current and future treatment strategies for rhabdomyosarcoma. Front Oncol. 2019;9:9. doi:10.3389/fonc.2019.01458
   PubMed Web of Science ®Google Scholar
• Dare AJ, Gupta AA, Thipphavong S, Miettinen M, Gladdy RA. Abdominal neoplastic manifestations of neurofibromatosis type 1. Neuro-Oncol Adv. 2020;2(Supplement_1):i124–i133. doi:10.1093/noajnl/vdaa032
   PubMedGoogle Scholar
• Kehrer-Sawatzki H, Cooper DN. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants. Hum Genet. 2022;141:177–191. doi:10.1007/s00439-021-02410-z
   PubMed Web of Science ®Google Scholar
• Madhaw G, Samanta R, Kumari S, Radhakrishnan DM, Shree R, Kumar N. Lisch nodule—ophthalmologic marker of Neurofibroma 1. QJM. 2019;112(12):934–935. doi:10.1093/qjmed/hcz098
   PubMed Web of Science ®Google Scholar
• Bouzas EA, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI. Lisch nodules in cushing’s disease. Arch Ophthalmol. 1993;111(4):439–440. doi:10.1001/archopht.1993.01090040029018
   PubMedGoogle Scholar
• Ma Y, Gross AM, Dombi E, et al. A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genet Med. 2020;22(11):1786–1792. doi:10.1038/s41436-020-0885-3
   PubMed Web of Science ®Google Scholar
• Viskochil DH, Stevenson DA. Skeletal Manifestations in NF1. In: Tadini G, Legius E, Brems H editors. Multidisciplinary Approach to Neurofibromatosis Type 1. Springer;2020. doi:10.1007/978-3-319-92450-2_7
   Google Scholar
• Shah H, Rousset M, Canavese F. Congenital pseudarthrosis of the tibia: management and complications. Indian J Orthop. 2012;46(6):616–626. doi:10.4103/0019-5413.104184
   PubMed Web of Science ®Google Scholar
• Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med. 2002;4(3):105–111. doi:10.1097/00125817-200205000-00002
   PubMed Web of Science ®Google Scholar
• Wang J, Wei G, Wang Z, et al. Detection of severe hypertension in a patient with neurofibromatosis type 1 during anesthesia induction: a case report. J Med Case Rep. 2019;13:349. doi:10.1186/s13256-019-2292-4
   PubMedGoogle Scholar
• Bergqvist C, Wolkenstein P. The Heart in Neurofibromatosis 1. In: Salavastru C, Murrell DF, Otton J editors. Skin and the Heart. Springer;2021. doi:10.1007/978-3-030-54779-0_7
   Google Scholar
• Rothner AD, Moodley M, Mientkiewicz L, Erenberg F. Congenital heart disease in neurofibromatosis-1 (P2.225). Neurology. 2015;84(14 Supplement):P2.225. doi:10.1212/WNL.84.14_supplement.P2.225
   Google Scholar
• Ognibene M, Scala M, Iacomino M, et al. Moyamoya vasculopathy in neurofibromatosis type 1 pediatric patients: the role of rare variants of RNF213. Cancers. 2023;15(6):1916. doi:10.3390/cancers15061916
   PubMed Web of Science ®Google Scholar
• Chelleri C, Scala M, De Marco P, et al. Case report: revascularization failure in NF1-related moyamoya syndrome after selumetinib: a possible pathophysiological correlation? Front Pediatr. 2023;11:1051026. PMID: 36923276; PMCID: PMC10010568. doi:10.3389/fped.2023.1051026
   PubMed Web of Science ®Google Scholar
• Scala M, Fiaschi P, Capra V, et al. When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience. Childs Nerv Syst. 2018;34:1311–1323. doi:10.1007/s00381-018-3833-7
   PubMed Web of Science ®Google Scholar
• Tortora D, Scavetta C, Rebella G, et al. Spatial coefficient of variation applied to arterial spin labeling MRI may contribute to predict surgical revascularization outcomes in pediatric moyamoya vasculopathy. Neuroradiology. 2020;62:1003–1015. doi:10.1007/s00234-020-02446-
   PubMed Web of Science ®Google Scholar
• Rivera AMC, Fernández-Villa T, Martín V, et al. Blunted circadian variation of blood pressure in individuals with neurofibromatosis type 1. Orphanet J Rare Dis. 2023;18:164. doi:10.1186/s13023-023-02766-7
   PubMed Web of Science ®Google Scholar
• Torres Nupan MM, Velez Van Meerbeke A, López Cabra CA, Herrera Gomez PM. Cognitive and behavioral disorders in children with neurofibromatosis type 1. Front Pediatrics. 2017;5. doi:10.3389/fped.2017.00227
   PubMed Web of Science ®Google Scholar
• Walsh KS, Janusz J, Wolters PL, et al. Neurocognitive outcomes in neurofibromatosis clinical trials: recommendations for the domain of attention. Neurology. 2016;87(7 Supplement 1):S21–S30. doi:10.1212/WNL.0000000000002928
   PubMedGoogle Scholar
• Debs P, Belzberg A, Blakeley J, et al. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution. Skeletal Radiol. 2023;2023:1. doi:10.1007/s00256-023-04511-4
   Google Scholar
• Toledano-Alhadef H, Mautner VF, Gugel I, et al. Role, function and challenges of multidisciplinary centres for rare diseases exemplified for neurofibromatosis type 1 syndrome. Childs Nerv Syst. 2020;36:2279–2284. doi:10.1007/s00381-020-04708-1
   PubMed Web of Science ®Google Scholar
• Wu-Chou YH, Hung TC, Lin YT, et al. Genetic diagnosis of neurofibromatosis type 1: targeted next-generation sequencing with multiple ligation-dependent probe amplification analysis. J Biomed Sci. 2018;25:72. doi:10.1186/s12929-018-0474-9
   PubMed Web of Science ®Google Scholar
• Radtke HB, Sebold CD, Allison C, et al. Neurofibromatosis type 1 in genetic counseling practice: recommendations of the national society of genetic counselors. J Genet Counsel. 2007;16:387–407. doi:10.1007/s10897-007-9101-8
   PubMedGoogle Scholar
• Wang MX, Dillman JR, Guccione J, et al. Neurofibromatosis from head to toe: what the radiologist needs to know. RadioGraphics. 2022;42(4):1123–1144. doi:10.1148/rg.210235
   PubMed Web of Science ®Google Scholar
• Winter N, Dohrn MF, Wittlinger J, et al. Role of high-resolution ultrasound in detection and monitoring of peripheral nerve tumor burden in neurofibromatosis in children. Childs Nerv Syst. 2020;36:2427–2432. doi:10.1007/s00381-020-04718-z
   PubMed Web of Science ®Google Scholar
• Hostetter J, Schwarz N, Klug M, et al. Primary care visits increase utilization of evidence-based preventative health measures. BMC Fam Pract. 2020;21:151. doi:10.1186/s12875-020-01216-8
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Viola F. Ocular Manifestations in Neurofibromatosis Type 1. In: Tadini G, Legius E, Brems H editors. Multidisciplinary Approach to Neurofibromatosis Type 1. Springer;2020. doi:10.1007/978-3-319-92450-2_6
   Google Scholar
• Moramarco A, Mallone F, Sacchetti M, et al. Hyperpigmented spots at fundus examination: a new ocular sign in Neurofibromatosis Type I. Orphanet J Rare Dis. 2021;16:147. doi:10.1186/s13023-021-01773-w
   PubMed Web of Science ®Google Scholar
• Bergqvist C, Wolkenstein P. Medical Follow-Up in Neurofibromatosis Type 1. In: Tadini G, Legius E, Brems H editors. Multidisciplinary Approach to Neurofibromatosis Type 1. Springer;2020. doi:10.1007/978-3-319-92450-2_19
   Google Scholar
• Korf BR. Malignancy in Neurofibromatosis Type 1. oncologist. 2000;5(6):477–485. doi:10.1634/theoncologist.5-6-477
   PubMedGoogle Scholar
• Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:81–88. doi:10.1136/jmg.2006.045906
   PubMed Web of Science ®Google Scholar
• Li J, Wei W, Xu F, Wang Y, Liu Y, Fu C. Clinical therapy of metastatic spinal tumors. Front Surg. 2021;2021:8. doi:10.3389/fsurg.2021.626873
   Google Scholar
• Mladenov KV, Spiro AS, Krajewski KL, et al. Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1). Childs Nerv Syst. 2020;36:2409–2425. doi:10.1007/s00381-020-04775-4
   PubMed Web of Science ®Google Scholar
• Nakao M, Shirotsuki K, Sugaya N. Cognitive–behavioral therapy for management of mental health and stress-related disorders: recent advances in techniques and technologies. BioPsychoSocial Med. 2021;15:16. doi:10.1186/s13030-021-00219-w
   PubMed Web of Science ®Google Scholar
• Browne T, Darnell J, Savage TE, Brown A. Social workers as patient navigators: a review of the literature. Social Work Res. 2015;39(3):158–166. doi:10.1093/swr/svv017
   Web of Science ®Google Scholar
• Rietman AB, Oostenbrink R, Bongers S, et al. Motor problems in children with neurofibromatosis type 1. J Neurodevelop Disord. 2017;9(19). doi:10.1186/s11689-017-9198-5
   PubMedGoogle Scholar
• Hagelskjær V, Nielsen KT, von Bülow C, et al. Occupational therapy addressing the ability to perform activities of daily living among persons living with chronic conditions: a randomised controlled pilot study of ABLE 2.0. Pilot Feasibility Stud. 2021;7:122. doi:10.1186/s40814-021-00861-9
   PubMedGoogle Scholar
• O’Sullivan M, Brownsett S, Copland D. Language and language disorders: neuroscience to clinical practice. Practical Neurology. 2019;19:380–388. doi:10.1136/practneurol-2018-001961
   PubMedGoogle Scholar
• Peduto C, Zanobio M, Nigro V, et al. Neurofibromatosis type 1: pediatric aspects and review of genotype–phenotype correlations. Cancers. 2023;15(4):1217. doi:10.3390/cancers15041217
   PubMed Web of Science ®Google Scholar
• Denayer E, Legius E. Legius syndrome and its relationship with neurofibromatosis type 1. Acta Derm. 2020;100(7):161–167. doi:10.2340/00015555-3429
   Google Scholar
• Zenker M, Edouard T, Blair JC, et al. Noonan syndrome: improving recognition and diagnosis. Arch Dis Child. 2022;107:1073–1078. doi:10.1136/archdischild-2021-322858
   PubMed Web of Science ®Google Scholar
• Serra G, Antona V, Corsello G, et al. NF1 microdeletion syndrome: case report of two new patients. Ital J Pediatr. 2019;45:138. doi:10.1186/s13052-019-0718-7
   PubMed Web of Science ®Google Scholar
• Kehrer-Sawatzki H, Cooper DN. Classification of NF1 microdeletions and its importance for establishing genotype/phenotype correlations in patients with NF1 microdeletions. Hum Genet. 2021;140:1635–1649. doi:10.1007/s00439-021-02363-3
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference. Neurofibromatosis. Conference statement. Arch Neurol. 1988;45(5):575–578. PMID: 3128965. doi:10.1001/archneur.1988.00520290115023
   PubMedGoogle Scholar
• Eaton RG, Lonser RR. Familial Neoplastic Syndromes. Neurol Clin. 2022;40(2):405–420. PMID: 35465883. doi:10.1016/j.ncl.2021.11.012
   PubMed Web of Science ®Google Scholar